A Look at Alignment Healthcare’s (ALHC) Valuation Following 2026 Medicare Advantage Expansion and Nevada Partnership

Alignment Healthcare (ALHC) recently unveiled its 2026 Medicare Advantage portfolio, expanding to 68 plan options in 45 counties across five states. This move also includes special needs plans and a new partnership in Nevada. The announcement comes ahead of the upcoming Medicare enrollment period.

See our latest analysis for Alignment Healthcare.

Alignment Healthcare’s announcement of its expanded Medicare Advantage portfolio and new Nevada partnership is a key highlight this quarter, and those moves appear to be building some cautious investor momentum. The company’s 1-year total shareholder return sits at 52.2%, signaling solid long-term gains. Its share price continues to reflect optimism around targeted growth in new regions and special needs plans.

If this wave of healthcare innovation grabs your interest, now is the ideal moment to discover other names in the space using our See the full list for free..

With shares riding a wave of strong returns and revenue growth, the real question for investors is whether Alignment Healthcare is still undervalued or if the market has already priced in the company’s next stage of expansion and innovation.

Most Popular Narrative: 12.9% Undervalued

The narrative consensus sets fair value at $19.09, compared to the last close of $16.62, suggesting room for further appreciation. With strong growth signals and evolving Medicare Advantage dynamics, the next catalyst may already be in play.

"Alignment's robust, technology-enabled care model and investments in administrative automation, workflow standardization, and digital health platforms position the company to significantly lower SG&A expenses and improve scalability. This will likely support both margin expansion and earnings growth over the next several years."

Read the complete narrative.

Curious how bold financial projections, rapid demographic shifts, and technology-driven cost efficiencies stack up to justify that price target? The full narrative unveils the surprising growth rates, forecasted margin leap, and factors shaping the future value. These are details you don't want to miss.

Result: Fair Value of $19.09 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, unexpected regulatory changes or increased competition could quickly curb Alignment Healthcare’s ambitious membership and margin growth trajectory.

Find out about the key risks to this Alignment Healthcare narrative.

Build Your Own Alignment Healthcare Narrative

If you think there’s a different story to tell or want to dig into the details yourself, crafting your own perspective can take just a few minutes, so why not Do it your way?

A great starting point for your Alignment Healthcare research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

Don’t let the next breakout opportunity slip away. Use Simply Wall Street to uncover new stocks that align with your goals and spark your investing journey.

• Uncover potential value by checking out these 896 undervalued stocks based on cash flows, a selection of stocks trading below their intrinsic worth for sharper portfolio growth.
• Catch the next wave of market innovation by spotting opportunities among these 24 AI penny stocks, which are shaping the future using advances in artificial intelligence.
• Maximize your returns with steady income from these 19 dividend stocks with yields > 3%, featuring companies with robust dividend yields above 3%.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com